Pharmacy Perspectives: Optimizing Treatment of Idiopathic Multicentric Castleman Disease
Release Date: October 29, 2021
Expiration Date: October 29, 2022
Time to Complete Activity: 1.0 hour
*This activity expired for credit on October 29, 2022 and is no longer available for credit
David C. Fajgenbaum, MD, MBA, MSc
Assistant Professor of Medicine
Division of Translational Medicine and Human Genetics
Associate Director, Patient Impact
Penn Orphan Disease Center
Center for Cytokine Storm Treatment and Laboratory
University of Pennsylvania
Co-Founder and Executive Director
Castleman Disease Collaborative Network
Ila M. Saunders, PharmD, BCOP
Associate Clinical Professor of Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Oncology Clinical Pharmacist, Moores Cancer Center
UC San Diego
La Jolla, CA
This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.
In collaboration with the Castleman Disease Collaborative Network
Disclosure of Financial Support
This activity is supported by an educational grant from EUSA Pharma (US) LLC.
This activity has been designed to address the educational needs of pharmacists in general, but specifically clinical pharmacists and hematology and oncology pharmacists. It will also benefit other clinicians interested in the management patients with CD.
This webinar will include a review of the pathophysiology of iMCD and how it applies to the development of current and emerging treatments. The expert faculty will discuss clinical trial data for current and emerging therapies, with a focus on efficacy, safety, appropriate dosing and formulations, drug-drug interactions, and pandemic-related considerations. Case studies will illustrate how pharmacists can apply evidence-based guideline recommendations to develop patient treatment plans.
Upon completion of this activity, participants should be able to:
- Review the pathophysiology of iMCD, including similarities and differences among the subtypes such as iMCD-TAFRO and iMCD-NOS
- Describe the MOAs of iMCD therapies and how they may relate to the pathophysiology of the disease
- Devise evidence-based, guideline-recommended treatment regimens to optimize outcomes of patients with iMCD
- Introduction to Castleman Disease
- Pathophysiology of iMCD
- Optimizing Treatment of iMCD With Guideline-Recommended Therapies
- Faculty Panel Discussion
Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.0 contact hours (0.10 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-21-325-H01-P
This is a knowledge-based activity.
Instructions for Participation
To receive a CPE certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CPE credit, contact the Paradigm CME Department at (845) 398-5949 or firstname.lastname@example.org.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at email@example.com.
In accordance with ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.
David Fajgenbaum, MD, MBA, MSc
Research Funding: EUSA Pharma
Ila M. Saunders, PharmD, BCOP
Advisor: EUSA Pharma
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Educational Review Systems, Inc. staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Educational Review Systems, Inc and Paradigm Medical Communications, LLC have implemented a system to resolve conflicts of interest for each CPE activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CPE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE guidelines.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Educational Review Systems, Inc or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As accredited providers, Educational Review Systems, Inc and Paradigm Medical Communications, LLC must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Educational Review Systems, Inc or Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Educational Review Systems, Inc or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Educational Review Systems, Inc or Paradigm Medical Communications, LLC. Educational Review Systems, Inc and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.
Educational Review Systems, Inc, Paradigm Medical Communications, LLC, or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CPE activity. All evaluative information submitted is collected and retained, and used by Educational Review Systems, Inc and Paradigm Medical Communications, LLC to continuously improve the learning experience.
Educational Review Systems, Inc and Paradigm Medical Communications, LLC do not transfer, sell, or share personal information with outside parties. Educational Review Systems, Inc and Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Educational Review Systems, Inc and Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at firstname.lastname@example.org.
© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.